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Background
The t(9;22) translocation leads to the formation of the chimeric breakpoint cluster region/c-abl
oncogene 1 (BCR/ABL) fusion gene on der22, the Philadelphia chromosome. The p185BCR/ABL or
the p210BCR/ABL fusion proteins are encoded as a result of the translocation, depending on
whether a “minor” or “major” breakpoint occurs, respectively. Both p185BCR/ABL and p210BCR/ABL
exhibit constitutively activated ABL kinase activity. Through fusion to BCR the ABL kinase in
p185BCR/ABL and p210BCR/ABL “escapes” the auto-inhibition mechanisms of c-ABL, such as allosteric
inhibition. A novel class of compounds including GNF-2 restores allosteric inhibition of the
kinase activity and the transformation potential of BCR/ABL. Here we investigated whether
there are differences between p185BCR/ABL and p210BCR/ABL regarding their sensitivity towards
allosteric inhibition by GNF-2 in models of Philadelphia chromosome-positive acute lymphatic
leukemia.
Design and Methods
We investigated the anti-proliferative activity of GNF-2 in different Philadelphia chromosome-
positive acute lymphatic leukemia models, such as cell lines, patient-derived long-term cultures
and factor-dependent lymphatic Ba/F3 cells expressing either p185BCR/ABL or p210BCR/ABL and their
resistance mutants.
Results
The inhibitory effects of GNF-2 differed constantly between p185BCR/ABL and p210BCR/ABL express-
ing cells. In all three Philadelphia chromosome-positive acute lymphatic leukemia models,
p210BCR/ABL-transformed cells were more sensitive to GNF-2 than were p185BCR/ABL-positive
cells. Similar results were obtained for p185BCR/ABL and the p210BCR/ABL harboring resistance muta-
tions.
Conclusions
Our data provide the first evidence of a differential response of p185BCR/ABL- and p210BCR/ABL- trans-
formed cells to allosteric inhibition by GNF-2, which is of importance for the treatment of
patients with Philadelphia chromosome-positive acute lymphatic leukemia.
Key words: Philadelphia chromosome, BCR/ABL, allosteric inhibition, acute lymphatic
leukemia, molecular therapy.
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Introduction
The der22 of t(9;22)(q34;q11), the so-called Philadelphia
chromosome (Ph), is detected in 95% of patients with
chronic myeloid leukemia, as well as in 20-30% of adult
acute lymphatic leukemia (ALL) patients. Chronic
myeloid leukemia is a myeloproliferative syndrome char-
acterized by an indolent chronic phase with an over-
growth of the mature myeloid cell population, which is, if
not treated, inevitably followed by an acute phase, the so-
called blast crisis. Clinically, the blast crisis resembles
acute leukemia, with a poor prognosis and resistance to
therapy.1-3 Chronic myeloid leukemia in blast crisis dis-
plays a myeloid phenotype in two-thirds of cases and a
lymphatic phenotype in the remaining one-third.4 In con-
trast, Ph+ ALL is an acute disease from the onset and is
characterized by blasts blocked at the pre-lymphatic stage
of differentiation. Patients suffering from Ph+ ALL consti-
tute a high-risk group.5 Lymphatic blast crisis and Ph+ ALL
are considered equivalent.1-3,6
On chromosome 22, the t(9;22) involves the Breakpoint
Cluster Region (BCR) gene locus. Two principal breaks
occur: the M-bcr, between exons 12 and 16 leading to the
creation of p210BCR/ABL, which is the hallmark of chronic
myeloid leukemia and the m-bcr, which maps to the first
intron of BCR and leads to the creation of p185BCR/ABL. The
breakpoint on chromosome 9 is constantly located in
intron 1 of the ABL gene locus.4 p185BCR/ABL is exclusive to
the Ph+ ALL, whereas p210BCR/ABL is found in about 30% of
Ph+ ALL as well as in chronic myeloid leukemia.4
p210BCR/ABL differs from p185BCR/ABL by the presence of the
putatively oncogenic Rho-GEF domain. Nevertheless,
only few functional and biological differences between
p210BCR/ABL and p185BCR/ABL are known.7 Both exhibit consti-
tutively activated kinase activity responsible for the induc-
tion of the leukemic phenotypes.5,8 Inhibition using ima-
tinib mesylate (imatinib), nilotinib or dasatinib, classical
ATP competitors, is a valid concept for the causal therapy
of Ph+ leukemia. 
The rapid acquisition of therapy resistance by patients
with advanced Ph+ lymphatic leukemia, together with fre-
quent features of patients, such as age or adverse side
effects, justify the need for novel approaches to the molec-
ular therapy of these diseases.9 One such novel approach
is the restoration of the allosteric inhibition of ABL-kinase
activity, one of the major auto-inhibitory mechanisms of
the ABL-kinase which is lost by fusion to BCR. Allosteric
inhibition occurs through the binding of the myristoylated
N-terminus (exon 1) to a hydrophobic pocket in the kinase
domain, the myristoyl binding pocket, followed by con-
formational changes that allow the intra-molecular dock-
ing of the SH2 domain to the kinase domain. This process,
called “capping”, leads to an auto-inhibited conformation
of c-ABL. The lack of the ”cap region” in exon 1 allows
BCR/ABL to “escape” auto-inhibition.10,11
In this study, we aimed to further develop allosteric
inhibition in Ph+ ALL by investigating the anti-proliferative
activity of GNF-2 in different Ph+ ALL models.
Design and Methods
Plasmids
The cDNA encoding p185BCR/ABL, p210BCR/ABL p185BCR/ABL Y253F,
p185BCR/ABL E255K, and p185BCR/ABL T315I have been described previ-
ously.15 The p210BCR/ABL Y253F, p185BCR/ABL E255K, and p185BCR/ABL
T315I were obtained by transfer of a KpnI fragment from
p185BCR/ABL E255K, and p185BCR/ABL T315I mutants to a KpnI digested
p210BCR/ABL in the pEntry vector (Gateway-Invitrogen, Karsruhe,
Germany). The resulting p210BCR/ABL mutant sequences were then
recombined in the PAULO destination vector by a Gateway reac-
tion according to the manufacturer’s instructions (Invitrogen). All
retroviral expression vectors used in this study were based on the
bi-cistronic vector PAULO.12
Cell lines 
The Ba/F3, BV-173, Tom-1 and Nalm-6 cells were obtained from
the German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany) and were maintained as previ-
ously described. Long-term cultures of cells derived from Ph+ ALL
patients (PD-LTC) were maintained in a serum–free medium con-
sisting of Iscove’s modified Dulbecco’s medium (IMDM) supple-
mented with 1 mg/mL of bovine insulin, 5¥10-5 M b–mercap-
toethanol (Sigma, Steinheim, Germany), 200 mg/mL Fe+–saturated
human apo–transferrin (Invitrogen, Karlsruhe, Germany), 0.6%
human serum albumin (Sanquin, Amsterdam, the Netherlands),
2.0 mM L–glutamine and 20 mg/mL cholesterol (Sigma).13
Transfection and retroviral infection were performed as previously
described.12 GNF-2 was dissolved in dimethylsulfoxide (DMSO)
(Sigma) for 1000 x stock solutions (50 mM, 100 mM, 150 mM, 250
mM, 300 mM, 500 mM, and 1 mM).
Cytotoxicity/proliferation 
Cytotoxicity/proliferation was assessed using the XTT prolifer-
ation kit according to the manufacturer’s instructions (Roche,
Mannheim, Germany). Cell growth was assessed by dye exclu-
sion using trypan-blue. The IC50 was calculated using Erithacus
software (Erithacus Ltd. East Grinstead, UK).
Western blotting
Western blotting was performed accordingly to widely estab-
lished protocols using the following antibodies: anti-ABL (α-ABL)
(St. Cruz Biotechnology, Santa Cruz, USA), anti-phospho-Y245
ABL (α-p-ABL-Y245), anti-CRKL (α-CRKL), and anti-phosphory-
lated CRKL (α-p CRKL)(Cell Signaling, Boston, USA).
Soft agar assay
PD-LTC (104 cells) were suspended in 1 mL “top-agar”, 0.25%
bacto-agar (DIFCO Laboratories, Detroit, USA) in IMDM and
stacked on 0.5% bacto-agar in Dulbecco’s modified Eagle’s medi-
um (DMEM) with 10% fetal calf serum (FCS) in six-well plates.
Colonies were counted after incubation for 15 days.
Results
Philadelphia chromosome-positive acute lymphatic
leukemia cell lines exhibit a differential response 
to GNF-2 which correlates with the expression 
of p185BCR/ABL or p210BCR/ABL 
To investigate the selective activity of the allosteric
inhibitor GNF-2 on Ph+ ALL, we compared the human
patient-derived cell lines Tom-1 and BV-173 expressing
p185BCR/ABL and p210BCR/ABL, respectively. Ph– Nalm-6 cells
were used as negative controls. These cell lines have a
nearly identical pre-B lymphatic differentiation level.
Cytotoxicity was assessed by the XTT and dye exclusion
assays. Here we show that GNF-2 inhibited proliferation
of BV-173 and Tom-1 cells with an IC50 of 125 nM and 500
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nM, respectively, without affecting the Nalm-6 cells
(Figure 1A). The growth of BV-173 and Tom-1 was
blocked completely at concentrations of 0.25 mM and 1
mM, respectively, whereas no effect was observed in
Nalm-6 cells (Figure 1B and data not shown). The differ-
ences in response to GNF-2 were not due to differences in
the expression levels of BCR/ABL between the Ph+ cell
lines (Figure 1C). In fact, the BV-173 cells expressed a high-
er level of BCR/ABL with a stronger basic autophosphory-
lation, as compared to Tom-1, whereas the effect of GNF-
2 on autophosphorylation was more pronounced in the
BV-173 cells than in the Tom-1 cells. In contrast, the
effects of GNF-2 on substrate phosphorylation (CRKL)
seemed to be more pronounced in the p185BCR/ABL-positive
Tom-1 cells than in the BV-173 cells (Figure 2C). Similar
results were obtained with other Ph+-positive ALL cell
lines, such as SupB15 (data not shown). 
Taken together, these data strongly suggest a different
response of Ph+-positive ALL cell lines to GNF-2 treatment
in accordance to the expression of either the p185BCR/ABL or
p210BCR/ABL fusion protein.
Philadelphia chromosome-positive patient-derived 
long-term culture cells expressing p210BCR/ABL are more
responsive to GNF-2 than those expressing p185BCR/ABL
Ph+ ALL in adults is not fully represented by cell lines. We,
therefore, compared the response of PD-LTC from Ph+ ALL
patients to GNF-2 in relationship to the cells’ expression of
p210BCR/ABL and p185BCR/ABL. The PD-LTC were directly
derived from bone marrow cells of Ph+ ALL patients cul-
tured in a specific culture medium.13 We compared the
responses from increasing concentrations of PD-LTC of two
Ph+ ALL patients expressing p185BCR/ABL (BV and PH) with
those of two patients expressing p210BCR/ABL (CM and VB).
As negative controls, we used the PD-LTC of a Ph- ALL
patient (HP). Cytotoxicity/proliferation was assessed at 72
h by XTT, as described above. GNF-2 inhibited the prolifer-
ation of both p210BCR/ABL- and p185BCR/ABL-expressing PD-LTC,
but with different IC50 values of 75-100 and 400-1000 nM,
respectively, and did not affect the proliferation of cells
from the Ph– ALL patient (Figure 2A). The PD-LTC were
able to form colonies in the semi-solid medium, demon-
strating their transformed phenotype (Figure 2B and data not
shown). The colony-forming potential of p210BCR/ABL-positive
PD-LTC, but not of p185BCR/ABL-positive PD-LTC, was signif-
icantly reduced by 250 nM and 500 nM of GNF-2. The dif-
ferential response was closely related to the variation in
inhibition of BCR/ABL kinase activity. GNF-2 only slightly
inhibited the autophosphorylation of p185BCR/ABL in cells
from the two Ph+ ALL patients expressing p185BCR/ABL (BV
and PH), whereas kinase activity was nearly abolished in
the p210BCR/ABL-expressing PD-LTC (from patients CM and
VB), even at low concentrations. In contrast to the substrate
phosphorylation of CRKL, which was only slightly affected
in p210BCR/ABL-positive but not in p185BCR/ABL-positive PD-LTC,
that of BCR and STAT5 was reduced in both but to a greater
extent in p210BCR/ABL -positive PD-LTC (Figure 2C).
In summary, these data show that Ph+ PD-LTC express-
ing p210BCR/ABL are more sensitive to GNF-2 than are those
expressing p185BCR/ABL.
Allosteric Inhibition of BCR/ABL in Ph+ ALL
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Figure 1. Effects of
GNF-2 on Ph+ cell
lines expressing
either p185BCR/ABL or
p210BCR/ABL (A) XTT
assay for Ph+ cells
expressing p185BCR/ABL
or p210 BCR/ABL upon
exposure to 0.25, 0.5
and 1 mM GNF-2. The
mean ± SD of tripli-
cates from one repre-
sentative experiment
out of three per-
formed is given. (B)
The number of viable
cells was determined
daily by trypan blue
dye exclusion. Data
represent the mean
± SD of three inde-
pendent experi-
ments. (C) Western
blot analysis of Ph+
cells using antibodies
directed against the
indicated proteins.
Molecular mass ref-
erences (KDa) are
presented. α-tubulin
was used as a load-
ing control.
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The BCR/ABL fusion proteins mediate differential 
sensitivity to GNF-2
To examine whether the differential effects of GNF-2
on Ph+ cell lines and PD-LTC are mediated by BCR/ABL
and to avoid the bias of yet unknown common or differ-
ing features of Ph+ ALL cells, we compared the effect of
GNF-2 on factor-dependent Ba/F3 cells, which become
factor-independent through the expression of either
p185BCR/ABL or p210BCR/ABL. Equal expression levels of
p185BCR/ABL and p210BCR/ABL were controlled by western blot-
ting excluding differences in transgene expression (Figure
3A). We exposed p185BCR/ABL- and p210BCR/ABL-expressing
Ba/F3 cells to increasing concentrations of GNF-2.
Cytotoxicity/proliferation and growth were assessed by
XTT and dye exclusion assays. The growth of p185BCR/ABL-
expressing cells was reduced to a maximum of 50%, even
at 2 mM of GNF-2; p210BCR/ABL-expressing cell growth, on
the other hand, was almost abolished at only 250 nM
(Figure 3B and C). 
The different sensitivity of p185BCR/ABL and p210BCR/ABL in
Ba/F3 cells to GNF-2 correlated with a different rate of
inhibition of the autophosphorylation. GNF-2 slightly
interfered with substrate phosphorylation of CRKL only
in p210BCR/ABL -positive Ba/F3 cells (Figure 3D).
In summary, these data show that the differential sensi-
tivity is mediated by the BCR/ABL fusion proteins
p185BCR/ABL and p210BCR/ABL.
BCR/ABL resistance mutants mediate differential 
sensitivity to GNF-2
The major clinical challenge in Ph+ leukemia is drug resist-
ance, which is mainly due to the acquisition by BCR/ABL
of point mutations such as the “P-loop” mutations Y253F
and E255K or the “gatekeeper” mutation T315I. We, there-
fore, investigated whether the differential sensitivity to
GNF-2 is exhibited  also by p185BCR/ABL and p210BCR/ABL harbor-
ing the Y253F, E255K or T315I point mutations. To do this
we compared the effect of GNF-2 on Ba/F3 cells which
became factor-independent through the expression of
p185BCR/ABL or p210BCR/ABL resistance mutants. We exposed the
cells to increasing concentrations of GNF-2.
Cytotoxicity/proliferation and growth were assessed by
XTT and dye exclusion assays. For clarity cell counts at day
3 of exposure are represented by bar graphs (Figure 4). We
found that the “P-loop” mutants of both p185BCR/ABL and
p210BCR/ABL responded to GNF-2 whereas the “gatekeeper”
a.a. mian et al.
254 haematologica | 2012; 97(2)
Figure 2. Effects of GNF-2 on PD-LTC of Ph+ ALL patients (A) XTT assay for PD-LTC cells expressing p185BCR/ABL or p210BCR/ABL upon exposure to
0.25, 0.5 and 1 mM GNF-2. The means ± SD of triplicates from one representative experiment out of three performed are given. (B) Soft
agar assay: PD-LTC expressing p185BCR/ABL or p210BCR/ABL were seeded at 104 cells/well in soft-agar in six-well-plates. After 15 days, the colonies
were counted, and the means ± SD of triplicates of one representative of two experiments performed are given. (C) Western blot analysis
of PD-LTC using antibodies directed against the indicated proteins.
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mutant T315I was completely refractory to GNF-2 (Figure
4A-C). p210BCR/ABL P-loop mutants showed a clearly greater
sensitivity to GNF-2 than their p185BCR/ABL counterparts.
Equal expression levels of p185BCR/ABL and p210BCR/ABL mutants
were controlled by western blotting, excluding differences
in transgene expression (Figure 4 A-C and data not shown). 
Taken together these data suggest that p210BCR/ABL P-loop
resistance mutants are more sensitive to allosteric inhibi-
tion by GNF-2 than are those of p185BCR/ABL, whereas the
“gatekeeper” mutation T315I confers complete resistance
independently of the BCR/ABL fusion protein.
Discussion
Allosteric inhibition is a novel approach for targeting
BCR/ABL. The aim of this study was to explore the effica-
cy and the clinical feasibility of allosteric inhibition in the
treatment of Ph+ ALL. We investigated the effects of GNF-
2 on both p185BCR/ABL- and p210BCR/ABL-positive ALL models.
We found that the allosteric inhibitor GNF-2, at clinically
feasible concentrations, effectively suppresses growth of
Ph+ ALL cells. In all models the p210BCR/ABL-positive cells
were more sensitive to GNF-2 than were the p185BCR/ABL-
Allosteric Inhibition of BCR/ABL in Ph+ ALL
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Figure 3. Effects of the allosteric inhibitor (GNF-2) on Ba/F3 cells expressing either p185BCR/ABL or p210BCR/ABL (A) Modular organization of the
p185BCR/ABL and p210 BCR/ABL and expression of the transgenes in Ba/F3 cells. (B) XTT assay for Ba/F3 cells expressing p185BCR/ABL or p210 BCR/ABL
upon exposure to 0.25, 0.5 and 1 mM GNF-2. The means ± SD of triplicates from one representative experiment out of three performed are
given. (C) For factor-independent growth, the number of viable cells was determined daily by trypan blue dye exclusion. The means ± SD of
three independent experiments are given. (D) Western blot analysis of Ba/F3 cells expressing the indicated transgenes using antibodies
directed against the indicated proteins.
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positive cells.
GNF-2 and its analogs are non-ATP competitive ABL
kinase inhibitors, which bind to the myristoyl binding
pocket in the kinase domain. It seems that the binding of
GNF-2 to this pocket stabilizes the protein in an inhibited
conformation,14 resulting in a structural reorganization of
ABL that disrupts the catalytic machinery located in the
ATP-binding region.14 This is in accordance with our
recent findings that the inhibition of oligomerization of
BCR/ABL - monomeric BCR/ABL is inactive - increases
the effects of GNF-2.15 Thus, one can speculate that the
variable sensitivities towards GNF-2 may be attributed to
differences in the overall conformations between
p185BCR/ABL and p210BCR/ABL due to the differences in the BCR
portion of the fusion proteins. These differences seem to
be  maintained also in resistance mutants, as suggested by
the greater sensitivity of the p210BCR/ABL forms as compared
to their p185BCR/ABL counterparts. In this case, GNF-2 may
have a different affinity for the myristoyl binding pocket.
Fusion partner influences on the allosteric inhibition of
ABL have been shown for another ABL fusion protein; the
TEL/ABL is able to confer factor-independent growth
through aberrant ABL-kinase activity but did not respond
to GNF-2.11 The reason for the resistance of the T315I
forms remains very unclear, even if the homo-oligomer-
ization or the hetero-oligemrization with BCR seems to
play a decisive role.15
The different sensitivity of p185BCR/ABL- and p210BCR/ABL-
positive Ph+ ALL cells is specific for GNF-2, because no dif-
ference was seen between BV-173 and Tom-1 regarding
their high sensitivity to imatinib (data not shown). On the
other hand the p185BCR/ABL-positive PD-LTC (from patients
BV and PH) differ for their response to imatinib but not for
that to GNF-2 (15 and data not shown).
The differential response of p185BCR/ABL- and p210BCR/ABL-
positive Ph+ ALL cells to allosteric inhibition can also be
seen as an expression of functional and biological differ-
ences most likely due to qualitative or quantitative differ-
ences in the kinase activity between p185BCR/ABL and
p210BCR/ABL, as previously shown.8,16,17 BCR/ABL kinase
activity is not characterized only by the autophosphoryla-
tion, but also by phosphorylation of substrates, such as
CRKL, STAT5 and BCR. It seems that GNF-2 is able to dis-
sociate features of the BCR/ABL kinase activity, because it
interferes with autophosphorylation but not with the
phosphorylation of all substrates to the same extent.
These effects may explain why GNF-2 only blocks prolif-
eration but does not induce apoptosis in BCR/ABL-trans-
formed cells.11,15 If this is the case, the higher basic kinase
activity of p185BCR/ABL may be responsible for its lower sen-
A.A. Mian et al.
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Figure 4. Effects of the allosteric inhibitor (GNF-2) on Ba/F3 cells expressing either p185BCR/ABL or p210BCR/ABL haboring resistance mutations.
Ba/F3 cells expressing p185BCR/ABL or p210 BCR/ABL harboring either the Y253F (A) the E255K (B) or the T315I mutation (C) were exposed to
0.25, 0.5, 1.0 and 2 mM GNF-2. XTT assays are shown in the upper panels. The means ± SD of triplicates from one representative experiment
out of three performed are given. For factor-independent growth, the number of viable cells was determined at day 3 by trypan blue dye
exclusion. The means ± SD of three independent experiments are given (middle panels). Western blot analysis of Ba/F3 cells expressing the
indicated transgenes using antibodies directed against the indicated proteins (lower panels).
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sitivity to allosteric inhibition as compared to p210BCR/ABL.
Our data presented here not only further establish
allosteric inhibition as an alternative molecular therapy
approach for the treatment of Ph+ ALL, but also evidence
the need for an accurate definition of the breakpoint on
der22 in order to optimize treatment. Furthermore there is
the need for alternative allosteric inhibitors of the ABL-
kinase, which overcome the partial resistance of p185BCR/ABL
and the related “P-loop” mutants to allosteric inhibition.
Collectively our data show a difference between
p185BCR/ABL and p210BCR/ABL with regard to their sensitivity
towards allosteric inhibition, a difference which must be
considered when using this novel approach for the treat-
ment of Ph+ ALL.
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